Accéder au contenu
Merck

Actual treatment of overactive bladder and urge urinary incontinence.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology (2013-03-30)
J N Cornu
RÉSUMÉ

Overactive bladder (OAB) is defined by its hallmark symptom, urgency. It can be associated with urge urinary incontinence (UUI), and dramatically impact the patients' quality of life. Etiologies of OAB are numerous, and under this common wording, virtually all the population is covered (men as well as women, patients with or without neurogenic disease, and all age categories). OAB and UUI management have been historically based on non-interventional therapies, antimuscarinics, and surgery. In the last decade, innovations in the treatment of this highly prevalent condition have been multiple, and further insights came from various horizons (drug invention, innovative use of existing drugs, new medical devices, tissue engineering, gene and cell therapy). Notably, the use of BoNT and neuromodulation techniques have deeply modified the algorithm of specialized OAB management, delaying surgery indications and offering mini-invasive alternatives to patient refractory to behavioral and medical treatment. Whilst some of these techniques are about to reach maturity, numerous questions remain unsolved about their indications, long term effects, rank in the armamentarium, cost-effectiveness, hypothetical combination or sequential use. The present review depicts the actual wide range of options available for OAB management in adults, focusing on the latest evolutions. When relevant, a distinction was made between genders and OAB subtypes (idiopathic vs neurogenic) regarding treatment outcomes.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Caféine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Caféine, powder, ReagentPlus®
Sigma-Aldrich
Caféine, anhydrous, 99%, FCC, FG
Supelco
Caféine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Caffeine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Caféine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Caféine, Sigma Reference Standard, vial of 250 mg
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Sigma-Aldrich
Caféine, anhydrous, tested according to Ph. Eur.
Supelco
Caféine, traceable to primary standards (LGC)
Supelco
Caffeine solution, analytical standard, 1.0 mg/mL in methanol
Sigma-Aldrich
Caféine, meets USP testing specifications, anhydrous
Sigma-Aldrich
Caféine, BioXtra
Sigma-Aldrich
Caféine, SAJ special grade, ≥98.5%
Caféine, European Pharmacopoeia (EP) Reference Standard
Caféine, European Pharmacopoeia (EP) Reference Standard